Lanthanum carbonate

From Wikipedia, the free encyclopedia
  (Redirected from Fosrenol)
Jump to: navigation, search
Lanthanum carbonate
Names
IUPAC name
Lanthanum carbonate
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.008.728
Properties
La2(CO3)3
Molar mass 457.838 g/mol
Appearance White powder, hygroscopic
Density 2.6–2.7 g/cm3
Melting point decomposes
negligible
Solubility soluble in acids
Pharmacology
V03AE03 (WHO)
Related compounds
Other anions
Lanthanum(III) oxide
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Lanthanum carbonate, La2(CO3)3, is the salt formed by lanthanum(III) cations and carbonate anions. It is an ore of lanthanum metal, along with monazite.

Chemistry[edit]

Lanthanum carbonate is used as a starting material in lanthanum chemistry, particularly in forming mixed oxides, for example

Medical uses[edit]

Lanthanum carbonate is used in medicine as a phosphate binder.[1] As a medication it is sold under the trade name Fosrenol by the pharmaceutical company Shire Pharmaceuticals. Due to its large size (1000mg tablet is 2.2cm in diameter), it may be possible to choke on the tablet if it is not chewed. It is prescribed for the treatment of hyperphosphatemia, primarily in patients with chronic kidney disease. It is taken with meals and binds to dietary phosphate, preventing phosphate from being absorbed by the intestine. For cats suffering from hyperphosphatemia it is available under the trade name Renalzin by Bayer Animal Health.[2]

However, when lanthanum carbonate is used for treating hyperphosphatemia, its side effects, namely myalgia, muscular cramping, and peripheral edema, should be clinically monitored.[3]

Other applications[edit]

Lanthanum carbonate is also used for the tinting of glass, for water treatment, and as a catalyst for hydrocarbon cracking.

References[edit]

  1. ^ Editorial Staff (December 2004). "Lanthanum Carbonate". All Micromedex Systems. Micromedex, Inc. Archived from the original on 2007-09-14. Retrieved 2007-11-25. 
  2. ^ Bayer Animal Health (26 September 2008). "Bayer Animal Health launches Renalzin for Cats" (PDF). Retrieved 2008-09-30. 
  3. ^ Tonelli, Marcello; Pannu, Neesh; Manns, Braden (2010). "Oral Phosphate Binders in Patients with Kidney Failure". New England Journal of Medicine. 362 (14): 1312. PMID 20375408. doi:10.1056/NEJMra0912522. 

External links[edit]